Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): positive results from AstraZeneca’s Phase III DURATION-8 study which assessed Bydureon (exenatide extended-release), a glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with Forxiga (dapagliflozin) the sodium glucose co-transporter-2 (SGLT2) inhibitor; a recommendation for approval of Boehringer Ingelheim’s and Eli Lilly’s Glyxambi (empagliflozin/linagliptin) by the European Medicines Agency CHMP; and positive data from Merck & Co.’s and Pfizer’s Phase III VERTIS SITA2 study for ertugliflozin in combination with sitagliptin and metformin.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved